Cardiovascular Disease in Patients With Chronic Myeloid Leukemia: JACC: CardioOncology State-of-the-Art Review

Abstract

Cardiovascular (CV) disease and risk factors are notably prevalent among patients with chronic myeloid leukemia (CML). The introduction of BCR::ABL1 tyrosine kinase inhibitors has significantly transformed the treatment paradigm for CML. However, it is imperative to recognize that these therapeutic agents may lead to CV side effects. For instance, dasatinib has been associated with the development of pulmonary arterial hypertension, while nilotinib and ponatinib have been linked to various vascular complications. To accurately evaluate the incidence of CV events associated with CML treatment, systematic documentation of these occurrences in future clinical trials is essential. This approach will facilitate a deeper understanding of the CV implications of tyrosine kinase inhibitor therapy in patients with CML.

Keywords: cardiovascular disease; chronic myeloid leukemia; coronary artery disease; imatinib; leukemia; nilotin; peripheral arterial disease; peripheral vascular disease; ponatinib; pulmonary hypertension; tyrosine kinase inhibitor.